BioNTech (NASDAQ:BNTX) and Novavax (NASDAQ:NVAX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Analyst Recommendations
This is a summary of current recommendations and price targets for BioNTech and Novavax, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
BioNTech | 0 | 4 | 3 | 0 | 2.43 |
Novavax | 1 | 0 | 6 | 0 | 2.71 |
BioNTech presently has a consensus price target of $105.50, indicating a potential downside of 20.44%. Novavax has a consensus price target of $229.6429, indicating a potential upside of 14.06%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than BioNTech.
Volatility & Risk
BioNTech has a beta of -1.74, indicating that its share price is 274% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500.
Valuation & Earnings
This table compares BioNTech and Novavax's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
BioNTech | $121.63 million | 262.50 | $-200,540,000.00 | ($0.95) | -139.58 |
Novavax | $18.66 million | 796.93 | $-132,690,000.00 | ($5.80) | -34.71 |
Novavax has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
10.8% of BioNTech shares are held by institutional investors. Comparatively, 49.9% of Novavax shares are held by institutional investors. 3.3% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares BioNTech and Novavax's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
BioNTech | -250.12% | -66.72% | -41.73% |
Novavax | -133.10% | -1,346.17% | -45.85% |
Summary
Novavax beats BioNTech on 10 of the 14 factors compared between the two stocks.